LYMPHOPROLIFERATIVE RESPONSE TO SYNTHETIC V3 LOOP P18 PEPTIDE AND HIV-1 ENVELOPE GLYCOPROTEIN AMONG INDIVIDUALS IMMUNIZED WITH GP160 CANDIDATE VACCINES
Z. Moukrim et al., LYMPHOPROLIFERATIVE RESPONSE TO SYNTHETIC V3 LOOP P18 PEPTIDE AND HIV-1 ENVELOPE GLYCOPROTEIN AMONG INDIVIDUALS IMMUNIZED WITH GP160 CANDIDATE VACCINES, Biomedicine & pharmacotherapy, 50(10), 1996, pp. 494-499
Citations number
22
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
Because T-cell responses are critical for defense against viral infect
ions, the synthetic P18 peptide (RIQRGPGRAFVTIGK) and active component
of gp160 protein has previously been shown to induce cytotoxic and he
lper T-lymphocyte responses. In order to further define the T-helper c
ells, responses which are known to play a role in enhancing the immuno
logical response to foreign antigen, we studied the response of indivi
duals immunized with HIV gp160 candidate vaccines. We investigated the
proliferative cellular response of peripheral blood mononuclear cells
(PBMC) derived from individuals immunized with gp160 antigens in thre
e different protocols. We found a PBMC proliferative response to synth
etic P18 peptide in healthy immunized individuals induced by Sp160 ant
igen with or without vaccinia virus, There was correlation between the
proliferative response to P18 peptide and other antigens such as HIV-
like proteins and gp160 molecule, HLA-DR typing revealed the possible
presentation of P18 peptide by several different class II molecules, S
ince these class II molecules occur frequently in the general populati
on, P18 peptide appears to contain broadly reactive epitopes and thus
is presented by mutiple HLA class II molecules. Due to its broad react
ivity P18 peptide is one of the candidates For inclusion as a subunit
vaccine against HIV-1.